McGill University Health Centre
McGill University Health Centre
Montreal, Canada6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Active, not recruiting | Phase 2 | 2026-09-21 | NCT07161037 | |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, disease arising from reactivation of latent virus, gram-positive bacterial infections, latent tuberculosis infection, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, tuberculosis | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05766267 | |
| 18F-FDG PET/CT for Diagnosis of Diabetic Foot Osteomyelitis | Diabetes Complications, Diabetic Foot, Foot Ulcer, Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, skin disorder, vascular disorder | Not yet recruiting | Not stated | 2026-09-18 | NCT07828691 | |
| A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypoglycemia, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 3 | 2026-09-01 | NCT04786262 | |
| COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events | Arterial Occlusive Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-06-03 | NCT05333068 | |
| A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-03-17 | NCT05257083 |